Table 1

Characteristics of 196 patients with recent onset IP and in those with and without IR

Variable at baseline

All pts

n = 196

IR

(HOMA IR ≥ 2.29)

n = 118 (60%)

No IR

HOMA IR < 2.29

n = 78 (40%)

P-value


Age when first seen (years)

49 (40 to 57)

49 (41 to 56)

48 (37 to 57)

0.49

Male gender

59 (30%)

38 (32%)

21 (27%)

0.43

Current smoker

50 (26%)

27 (23%)

23 (29%)

0.30

Obese (BMI ≥ 30)

57 (30%)

46 (40%)

11 (15%)

< 0.001

On treatment for or diagnosed with DM

26 (13%)

16 (14%)

10 (13%)

0.88

Fasting blood glucose (mmol/L) *

4.7 (4.4 to 5.0)

4.8 (4.5 to 5.1)

4.5 (4.3 to 4.8)

< 0.001

Fasting insulin (μU)

12.7 (8.9 to 18.1)

16.7 (13.2 to 21.6)

8.2 (6.0 to 9.4)

< 0.001

HOMA-IR

2.7 (1.8 to 3.9)

3.5 (2.8 to 4.8)

1.6 (1.2 to 1.9)

< 0.001

SBP (mmHg) *

132 (17)

135 (17)

129 (15)

0.04

DBP (mmHg) *

81 (10)

83 (10)

79 (9)

0.01

On treatment for hypertension

19 (10%)

13 (11%)

6 (8%)

0.44

TG (mmol/L) *

1.4 (0.6)

1.6 (0.6)

1.1 (0.5)

< 0.001

T.Chol (mmol/L) *

5.4 (1.1)

5.5 (1.1)

5.2 (1.1)

0.24

HDL (mmol/L) *

1.5 (0.4)

1.5 (0.5)

1.6 (0.4)

0.03

LDL (mmol/L) *

3.2 (0.9)

3.3 (0.9)

3.1 (0.9)

0.43

On statin treatment

11 (6%)

5 (4%)

6 (8%)

0.30

IP symptom duration (months)

6.7 (4.6 to 10.7)

6.5 (4.5 to 9.9)

7.0 (4.7 to 11.8)

0.28

Age at IP symptom onset

48 (40 to 56)

48 (40 to 55)

48 (36 to 57)

0.42

RF positive

90 (47%)

63 (55%)

27 (35%)

0.01

ACPA positive

66 (34%)

50 (44%)

16 (21%)

< 0.001

Fulfil ACR criteria for RA

87 (44%)

58 (49%)

29 (37%)

0.10

Swollen joint count (/51)

4 (1 to 7)

4 (2 to 9)

4 (1 to 7)

0.44

Tender joint count (/51)

8 (2 to 18)

8 (2 to 18)

9 (3 to 17)

0.87

Both swollen & tender (/51)

2 (0 to 6)

2 (0 to 6)

2 (0 to 5)

0.96

CRP (mg/L)

10 (7 to 17)

11 (5 to 21)

9 (7 to 13)

0.21

DAS28CRP

3.9 (3.0 to 4.8)

3.9 (3.0 to 4.9)

3.9 (3.1 to 4.7)

0.73

HAQ

0.88 (0.38 to 1.38)

0.88 (0.38 to 1.68)

0.88 (0.38 to 1.38)

0.26

On steroids

prior to baseline assessment

43 (22%)

24 (20%)

19 (24%)

0.51

On DMARDs

prior to baseline assessment

105 (54%)

67 (57%)

38 (49%)

0.27

On MTX prior to baseline assessment

60 (31%)

36 (31%)

24 (31%)

0.97

On HCQ prior to baseline assessment

11 (6%)

6 (5%)

5 (6%)

0.69


All data are presented as n (%) except where we indicate that either median (IQR) or mean (SD) * were used.

ACPA, anti-CCP antibody; ACR, American College of Rheumatology; CRP, C-reactive protein; DAS 28CRP , Disease Activity Score calculated using CRP; DBP, diastolic blood pressure; DM, diabetes mellitus; HAQ, Health Assessment Questionnaire; HCQ, hydroxychloroquine; HDL, high density lipoprotein; HOMA-IR, Homeostatic Model Assessment for Insulin Resistance; IP, inflammatory polyarthritis; LDL, low density lipoprotein; MTX, methotrexate; RF, rheumatoid factor; SBP, systolic blood pressure;

T.chol, total cholesterol; TG, triglycerides

Mirjafari et al. Arthritis Research & Therapy 2011 13:R159   doi:10.1186/ar3476

Open Data